Search research articles
Contact Us
Filters
Showing results (91-100 of 165) with videos related to
Page
of 17
Sort By:
The Lancet. Oncology
|
October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
Jaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Bone Marrow Transplantation
|
March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
Gesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
British Journal of Haematology
|
November 24, 2018
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid, Myriam Labopin, Nicolaas Schaap, et al.
Transplantation and Cellular Therapy
|
December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study Group
Christina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Plos One
|
January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study
Utz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
Haematologica
|
September 18, 2012
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
Tim Pfeiffer, Michael Schleuning, Jiri Mayer, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
February 15, 2026
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany
Marie Engelhard, Sebastian M Wingen-Heimann, Annika Y Classen, et al.
Blood
|
March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Jan M Middeke, Min Fang, Jan J Cornelissen, et al.
Annals of Hematology
|
April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
Felicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Bone Marrow Transplantation
|
July 3, 2024
Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT)
Gesine Bug, Myriam Labopin, Alexander Kulagin, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 165) with videos related to
Sort By:
Page
of 17
The Lancet. Oncology
|
October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
Jaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Bone Marrow Transplantation
|
March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
Gesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
British Journal of Haematology
|
November 24, 2018
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid, Myriam Labopin, Nicolaas Schaap, et al.
Transplantation and Cellular Therapy
|
December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study Group
Christina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Plos One
|
January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study
Utz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
Haematologica
|
September 18, 2012
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
Tim Pfeiffer, Michael Schleuning, Jiri Mayer, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
February 15, 2026
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany
Marie Engelhard, Sebastian M Wingen-Heimann, Annika Y Classen, et al.
Blood
|
March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Jan M Middeke, Min Fang, Jan J Cornelissen, et al.
Annals of Hematology
|
April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
Felicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Bone Marrow Transplantation
|
July 3, 2024
Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT)
Gesine Bug, Myriam Labopin, Alexander Kulagin, et al.
Page
of 17